Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Change in Acquisitions & Divestments (2020 - 2025)

RxSight (RXST) has disclosed Change in Acquisitions & Divestments for 6 consecutive years, with $90.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 63.64% year-over-year to $90.0 million, compared with a TTM value of $260.0 million through Dec 2025, up 7.0%, and an annual FY2025 reading of $260.0 million, up 7.0% over the prior year.
  • Change in Acquisitions & Divestments was $90.0 million for Q4 2025 at RxSight, up from $60.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $90.0 million in Q1 2022 and bottomed at $15.0 million in Q3 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $54.6 million, with a median of $55.0 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments skyrocketed 400.0% in 2022, then tumbled 33.33% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $25.0 million in 2021, then surged by 80.0% to $45.0 million in 2022, then increased by 11.11% to $50.0 million in 2023, then increased by 10.0% to $55.0 million in 2024, then soared by 63.64% to $90.0 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for RXST at $90.0 million in Q4 2025, $60.0 million in Q3 2025, and $50.0 million in Q2 2025.